How many insider trades does FilingIQ track for DRMA?

FilingIQ tracks 77 Form 4 insider transactions for DRMA (Dermata Therapeutics, Inc.), covering filings from Aug 16, 2021 onwards. 1 of those were filed in the last 90 days.

Are DRMA insiders net buyers or net sellers?

Across the full Form 4 history for DRMA, 5 transactions (6%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does DRMA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is DRMA in?

Dermata Therapeutics, Inc. (DRMA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.90M.

DRMA insider trading

NasdaqCM Healthcare

Dermata Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

6% / 0%

Market cap

$3.90M

About Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Company website: www.dermatarx.com

DRMA insider activity at a glance

FilingIQ has scored 77 insider transactions for DRMA since Aug 16, 2021. The most recent filing in our index is dated Feb 17, 2026.

Across the full history, 5 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on DRMA insider trades is 67.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live DRMA trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for DRMA?: FilingIQ tracks 77 Form 4 insider transactions for DRMA (Dermata Therapeutics, Inc.), covering filings from Aug 16, 2021 onwards. 1 of those were filed in the last 90 days.
Are DRMA insiders net buyers or net sellers?: Across the full Form 4 history for DRMA, 5 transactions (6%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does DRMA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is DRMA in?: Dermata Therapeutics, Inc. (DRMA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.90M.

Methodology & sources

Every DRMA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.